EOLS FY 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$295M+10.8% YoY

Gross Profit

$197M66.8% margin

Operating Income

-$33M-11.1% margin

Net Income

-$52M-17.5% margin

EPS (Diluted)

$-0.80

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$46M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$226M

Total Liabilities

$249M

Stockholders' Equity

-$23M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$295M	$266M	+10.8%
Gross Profit	$197M	$182M	+8.1%
Operating Income	-$33M	-$34M	+5.1%
Net Income	-$52M	-$50M	-2.4%